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INTRODUCTION
Dendritic cells (DC) are professional anti-
gen presenting cells (APCs) that play a
pivotal role in the induction and reg-
ulation of immune responses, including
the induction of cytotoxic T lympho-
cyte (CTL) responses. They are an impor-
tant focus for the development of vac-
cines against cancers and many pathogens,
including HIV and malaria, where CTL
responses are required for protection and
disease eradication. DC loaded ex vivo with
tumor antigen (Ag) have been adminis-
tered as vaccines to cancer patients for
over 15 years. They are well-tolerated and
induce immune responses, including some
clinical regressions, but there is clearly
room for improvement (1). The DC net-
work in both mice and humans is hetero-
geneous, with specialized DC subsets dri-
ving specific immune functions (2). New
developments in our understanding of DC
biology have identified a subset of DC char-
acterized by the expression of novel mark-
ers CLEC9A (DNGR-1) (3, 4) and XCR1
(5, 6) as being important for the induction
of CTL responses (7). Vaccine strategies
that deliver Ag and activators directly to
CLEC9A+XCR1+ DC in vivo promise to
overcome many of the logistical issues asso-
ciated with in vitro-derived vaccines, allow-
ing precision and specificity of the desired
immune response (8). Here, we discuss the
biological properties of CLEC9A+XCR1+
DC that make them such attractive tar-
gets for CTL vaccines and new vaccine
approaches to target them in vivo.
CLEC9A+XCR1+ DC ARE ESSENTIAL
FOR CTL INDUCTION
The emerging complexity of the DC net-
work and the optimal DC subset to tar-
get is the first important consideration for
the design of new vaccines that target DC
in vivo. In human and mouse, multiple DC
subsets exist that vary in location, pheno-
type, and specialized function (2). They can
be broadly classified as (i) inflammatory
monocyte-derived (Mo) DC that develop
from monocytes and are rapidly recruited
to sites of inflammation; (ii) plasmacytoid
DC (pDC) that are major producers of type
I interferons (IFN) in response to TLR 7/9
ligation and are key for anti-viral immu-
nity; and (iii) conventional DC (cDC) that
can be further divided based on loca-
tion into “lymphoid-resident” and “migra-
tory” DC (2). The lymphoid-resident DC
capture Ag directly in lymphoid tissues,
whereas the migratory DC reside in the
peripheral organs (e.g. lung, skin, and gut)
where they capture Ag then migrate to
lymphoid tissues to share their Ag with
other lymphoid-resident DC, or present
Ag directly to T cells. In both locations,
cDC can be further segregated into sub-
sets with specialized functions. Increasing
evidence points to a role for the mouse
CD11b+ cDC subset in the induction of
CD4+ T cell responses although a simi-
lar role for the equivalent human CD1c+
DC subset has not yet been established (2,
9). However, it is the subset defined by
expression of the C-type lectin-like recep-
tor, CLEC9A, and the chemokine receptor,
XCR1, that is crucial for the induction of
CTL responses against cancers, viruses, and
other pathogenic infections (2, 7).
CLEC9A+XCR1+ DC were originally
identified in mice by expression of the
markers CD8α on lymphoid-resident DC
or CD103 on migratory DC and are com-
monly referred to as CD8α+ lymphoid
and CD103+ migratory DC. In humans,
CLEC9A+XCR1+ DC, commonly referred
to as CD141+ DC, are found in both lym-
phoid and non-lymphoid tissues, includ-
ing skin, gut, liver, and lungs (6, 10–
13). CLEC9A and XCR1 are exclusively
expressed by this unique DC subset in lym-
phoid and non-lymphoid tissues of both
species, with the exception of low levels
of expression of Clec9A by mouse pDC.
As these markers combined are currently
the most specific means of defining these
DC in both species, we hereafter refer to
them as CLEC9A+XCR1+ DC. In addi-
tion to CLEC9A and XCR1, these DC share
expression of the nectin-like protein, Necl2
(14) and TLR3, and are major producers
of IFN-λ after TLR3 ligation (15). Impor-
tantly, they excel at cross-presentation, the
mechanism that allows exogenous Ag, such
as that captured from tumors and virally
infected cells to be processed and presented
on MHC I for recognition by CTLs (16).
WHAT MAKES CLEC9A+XCR1+ DC SO
EFFECTIVE AT CTL PRIMING?
Although other cell types, including
macrophages, B cells, and other DC sub-
sets, can cross-present under particular
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circumstances in vitro (17–20), there is
substantial evidence to demonstrate that
CLEC9A+XCR1+ DC are inherently more
efficient at this process in vitro and in vivo
(6, 7, 10, 11, 16). The precise molecu-
lar mechanisms are not understood but
extensive efforts have yet to reveal special-
ized cross-presentation machinery unique
to CLEC9A+XCR1+ DC (16). However,
there are several features of these DC that
collectively explain their superior cross-
priming ability despite a similar Ag uptake
capacity compared with other DC subsets.
Firstly, CLEC9A+XCR1+ DC maintain a
less acidic pH in endosomes and phago-
somes, favoring cross-presentation from
early endocytic vesicles (21), and facilitat-
ing cross-presentation of Ag targeted to
late endosomes/lysosomes (20, 22). Sec-
ondly, CLEC9A+XCR1+ DC are more effi-
cient at translocation of Ag from endo-
somes/phagosomes into the cytosol for
access to the classical MHC I processing
pathway (23). Thirdly, CLEC9A, a receptor
for actin filaments exposed on dead cells,
plays a key role in delivering Ag captured
from dead cell for cross-priming (24–27).
Fourthly, CLEC9A+XCR1+ DC express
high levels of TLR3, a known enhancer
of cross-priming (28). Finally, consti-
tutive activation of unfolded-protein-
response sensor, IRE-1α, and the tran-
scription factor XBP-1 was recently shown
to regulate cross-presentation specifically
by CLEC9A+XCR1+ DC (29). There
is also evidence that XCR1 and Necl2
are involved in CTL activation, although
not directly via augmenting the cross-
presentation pathway (5, 6, 14). These fea-
tures provide a strong rationale to develop
technologies that specifically deliver Ag
to the cross-presentation pathway of
CLEC9A+XCR1+DC in vivo.
TARGETING CLEC9A+XCR1+DC IN VIVO
Antibodies (Ab) specific for DC surface
receptors, particularly Ag uptake receptors,
can be harnessed to deliver Ag directly to
DC in vivo (30). The choice of receptor
depends on its specificity for the DC sub-
set to be targeted in addition to the Ag
processing and presentation pathway used
by the receptor following internalization.
A variety of C-type lectin receptors (CLR)
have been exploited for this purpose, and
this is reviewed elsewhere (1, 30) but for
delivering Ag to CLEC9A+XCR1+ DC in
mice, DEC-205 has been a major focus.
Delivery of Ag via DEC-205 Ab induces
both CD4+ and CD8+ T cell responses
in the presence of adjuvant and is supe-
rior to ex vivo loaded DC vaccines at pre-
venting tumor growth [reviewed elsewhere
(31)]. Phase I/II clinical trials targeting
NY-ESO-1 Ag for treatment of multiple
solid malignancies expressing this Ag are
in progress utilizing CDX-1401, a fully
humanized Ab against DEC-205 (CellDex
Therapeutics). In humans, DEC-205 is
widely expressed on all DC, in addition
to B cells, T cells, and NK cells. Although
CLEC9A+XCR1+ DC, CD1c+ DC, pDC,
and MoDC have been shown to process and
present Ag delivered by DEC-205 to CD4+
and CD8+ T cells in vitro (20, 31–33), lim-
ited direct comparisons suggest CLEC9A+
XCR1+ DC to be more effective at cross-
presentation (20). This is likely due to
the preferential trafficking of DEC-205 to
late endosomes, which typically favors Ag
processing via the MHC II pathway (34),
whilst still allowing cross-presentation by
CLEC9A+XCR1+ DC (20).
An attractive approach is to more specif-
ically deliver Ag to CLEC9A+XCR1+ DC
using Ab or ligands specific for CLEC9A (3,
4) or XCR1 (35). Studies utilizing Clec9A
for Ag delivery in mice observe effective
CD8+ T cell responses and, surprisingly,
superior CD4+ T cell immunity when
directly compared to DEC-205, even in the
absence of adjuvant (3, 4, 36). Key reasons
for the efficacy of targeting Clec9A include
its intracellular trafficking, as Clec9A deliv-
ers Ag to early and recycling endosomes
(27), and the persistence of anti-Clec9A
Ab in serum, resulting in prolonged Ag
presentation (36). Determining the mol-
ecular interactions of CLEC9A following
internalization and how this influences Ag
trafficking and processing, will undoubt-
edly shed light on the basis for Clec9A
targeting efficacy.
Anti-human CLEC9A Ab can deliver
Ag to human CLEC9A+XCR1+ DC for
processing and presentation to both
CD4+ and CD8+ T cell lines in vitro
(37). This provides proof-of-principle and
a strong rationale to further develop
anti-human CLEC9A Ab for vaccines
and more comprehensively compare with
DEC-205 Ab and other approaches that
target multiple DC subsets. Such studies
have been limited due to difficulties in
obtaining sufficient numbers of human
CLEC9A+XCR1+ DC for detailed func-
tional analysis, but are now feasible
with the development of new humanized
mouse models, where functional human
CLEC9A+XCR1+ DC develop and can be
targeted with CLEC9A or DEC-205 Abs
in vivo (38).
ADJUVANTS FOR ACTIVATION OF
CLEC9A+XCR1+DC
Early DC clinical trials and mouse stud-
ies investigating Clec9A or DEC-205 tar-
geting Ab have clearly demonstrated a
requirement for DC activation in order
to induce optimal CTL responses (31,
39). TLR ligands are some of the most
promising adjuvants currently being eval-
uated in the clinic and differential expres-
sion of TLR by DC subsets could pro-
foundly affect the choice of adjuvant.
This is a particularly important consid-
eration for the preclinical evaluation of
vaccines targeting CLEC9A+XCR1+ DC
since TLR expression varies in mouse and
human DC subsets. The TLR9 ligand, CpG,
has been widely used as an adjuvant in
mice, including with Clec9A Ab (36) and
has been evaluated clinically, with lim-
ited adverse effects, as an adjuvant in can-
cer chemotherapy and ex vivo DC vac-
cines (40). Whilst TLR9 is widely expressed
in mice, including by CLEC9A+XCR1+
DC, in humans it is restricted to pDCs
(39). However, activation of human pDC
by CpG induces large amounts of type
I IFN that could potentially play an
important bystander function for activa-
tion of CLEC9A+XCR1+ DC and subse-
quent induction of anti-tumor responses
(41, 42). In contrast to their mouse coun-
terparts, human CLEC9A+XCR1+ DC also
lack expression of TLR4 but express TLR8,
which is not functional in mice (39).
A TLR7/8 ligand, R848 or resiquimod,
has been FDA approved for topical use
and is currently undergoing clinical trials
with DEC-205 (CDX-1401, CellDex) (43).
It also activates CD1c+ DC via TLR8 and
pDC via TLR7. Its potential to be used in
vaccines remains to be determined, with
murine studies indicating that its short
half-life and formulation may not be ideal
for activating DC locally to initiate adap-
tive immune responses, and it has been
implicated in severe side effects observed
in clinical trials (43).
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The TLR3 ligand, polyI:C, is emerg-
ing as an attractive adjuvant to combine
with DC targeting Ab, as TLR3 expres-
sion is conserved across human and mouse
CLEC9A+XCR1+ DC. PolyI:C was found
to be the optimal adjuvant to use in combi-
nation with DEC-205 targeting Ab in mice
(44). The poly I:C derivatives Hiltonol and
Ampligen are well-tolerated in humans and
induce a type I IFN response mimicking
that of a viral infection (45). These are now
being evaluated in clinical trials in conjunc-
tion with DEC-205 targeting Ab (CellDex
Therapeutics; NCT00948961).
CONCLUSION
There remains a great need for the develop-
ment of vaccines that elicit effective anti-
viral and anti-tumor CTL responses. The
discovery of the CLEC9A+XCR1+DC in
mice and humans, as a subset special-
ized for Ag cross-presentation and cross-
priming CTL, has revealed promising new
avenues for vaccine design. Yet, the contri-
bution of other DC subsets to the efficacy of
this process is still to be determined. Thus,
the questions remain: is it more effective to
deliver Ag to the CLEC9A+XCR1+DC that
are best-equipped for cross-presentation,
or will co-delivery to other DC sub-
sets provide help? Which receptors will
best deliver the Ag to the required intra-
cellular compartments, and which adju-
vants will best enhance immune responses?
Studies to date suggest that targeting
CLEC9A+XCR1+ DC in vivo, together
with adjuvants to specifically activate these
DC, offers great promise. The advancement
of humanized mouse models allowing for
development of CLEC9A+XCR1+ DC and
other DC subsets, will enable these and
other questions to be answered, and facili-
tate translation from bench to bed-side.
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